

**Proteon Therapeutics, Inc.**  
**200 West Street**  
**Waltham, MA 02145**  
**(781) 890-0102**

February 5, 2019

**Via EDGAR and FedEx**

United States Securities and Exchange Commission  
Division of Corporate Finance  
100 F Street, NE  
Washington, D.C. 20549  
Attn: Donald E. Field

RE: Proteon Therapeutics, Inc.  
Registration Statement on Form S-3  
SEC File No. 333-228865

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Proteon Therapeutics, Inc., a Delaware corporation (the "Company"), hereby respectfully requests that the effectiveness of the Company's above-referenced Registration Statement on Form S-3, as amended, be accelerated to **4:00 p.m. Eastern Time, on February 7, 2019** or as soon as practicable thereafter.

Should you have any questions regarding this request, please do not hesitate to contact Tara R. McElhiney at (713) 890-5732 of Morgan, Lewis & Bockius LLP, counsel to the Company.

Sincerely,

PROTEON THERAPEUTICS, INC.

/s/ George A. Eldridge

Name: George A. Eldridge  
Title: Senior Vice President, Chief Financial  
Officer, Treasurer and Assistant Secretary

cc: Matthew Kowalsky, Proteon Therapeutics, Inc.  
Julio E. Vega, Morgan, Lewis & Bockius LLP  
Tara R. McElhiney, Morgan, Lewis & Bockius LLP